MAP2K7/MEK7

MAP2K7, also known as MEK7 or MKK7, functions as a dual-specificity kinase in the mitogen-activated protein kinase (MAPK) signaling cascade, directly phosphorylating and activating JNK under stress or mitogenic stimulation^[1]. Mechanistically, MAP2K7 occupies a critical upstream position in the MAPK cascade, allowing it to modulate proliferation, differentiation, and stress-response pathways^[1]. Compared with related MEK isoforms, MAP2K7 selectively activates JNK rather than ERK, establishing a distinct signaling branch within the MAPK family^[1][2]. Dysregulation of MAP2K7 contributes to pediatric T cell acute lymphoblastic leukemia (T-ALL), where aberrant JNK signaling drives leukemic cell survival and proliferation^[1]. In experimental models, pharmacological inhibition of MAP2K7 using rationally designed covalent inhibitors reduces JNK activation and downstream transcriptional programs, providing a tool for functional studies and potential therapeutic exploration^[1]. Additionally, genetic and pharmacological perturbation of MAP2K7 can modulate feedback loops in RAS/MAPK-driven cancers, highlighting its relevance in combination treatment strategies^[3][2]. Structural analyses reveal unique binding motifs that confer selectivity and facilitate rational inhibitor design, distinguishing MAP2K7 from other MEKs with overlapping catalytic domains^[1][4]. Overall, MAP2K7 serves as a distinct molecular node within the MAPK network, integrating upstream signals into JNK-specific responses with translational potential for targeted intervention^[1][3].